Notably, inhibition of dopamine D2 receptors on indirect pathway MSNs is putatively the mechanism of antipsychotic action of the D2 receptor antagonists, the standard of care pharmacotherapy for the treatment of psychosis in schizophrenia (Seeman, 2010; McCutcheon et al., 2019). Here, DRD2 is linked to schizophrenia.